XOMA Royalty to Acquire HilleVax for $1.95 Per Share Plus CVR
XOMA Royalty Corporation’s acquisition of Hillevax for $1.95 per share in cash, plus a contingent value right (CVR), marks...
XOMA Royalty Corporation’s acquisition of Hillevax for $1.95 per share in cash, plus a contingent value right (CVR), marks...
Lift Biosciences Secures €12M Grant to Advance “First-in-Class” Neutrophil Immunotherapy. Lift Biosciences has secured a €12 million grant from...
Full Alliance Group Signals Ambitious Growth Trajectory in Q2 2025 Results Full Alliance Group (FAGI) has announced preliminary unaudited...
Orchestra Biomed Secures $70M in Strategic Funding, Expanding Cardiovascular Pipeline and Partnerships Orchestra Biomed has secured $70 million in...
Poltreg Secures FDA Support for Registrational Trial in Pre-Symptomatic Type 1 Diabetes Poltreg, a Polish biotech specializing in T-regulatory...
Supernus Pharmaceuticals has finalized its acquisition of Sage Therapeutics, marking a significant shift in the CNS treatment landscape. This...
VedtechBio Research Pvt. Ltd. has significantly enhanced its AI-driven drug discovery platform, RxAgentAI™, claiming a halving of drug development...
Sanofi’s Q2 2025 results reveal a company navigating a complex landscape of patent expirations, new launches, and strategic acquisitions....
Insight Molecular Diagnostics (IMDX) has unveiled compelling data at the World Transplant Congress, showcasing a novel approach to quantifying...
Sirona Biochem, a cosmetic ingredient and drug discovery company, is facing significant financial distress, culminating in the liquidation of...